|Other Names||cAMP-dependent protein kinase type I-alpha regulatory subunit, Tissue-specific extinguisher 1, TSE1, cAMP-dependent protein kinase type I-alpha regulatory subunit, N-terminally processed, PRKAR1A, PKR1, PRKAR1, TSE1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP8095a was selected from the N-term region of human PKR1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||PKR1, PRKAR1, TSE1|
|Function||Regulatory subunit of the cAMP-dependent protein kinases involved in cAMP signaling in cells.|
|Cellular Location||Cell membrane.|
|Tissue Location||Four types of regulatory chains are found: I- alpha, I-beta, II-alpha, and II-beta. Their expression varies among tissues and is in some cases constitutive and in others inducible|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
cAMP is a signaling molecule important for a variety of cellular functions. cAMP exerts its effects by activating the cAMP-dependent protein kinase (AMPK), which transduces the signal through phosphorylation of different target proteins. The inactive holoenzyme of AMPK is a tetramer composed of two regulatory and two catalytic subunits. cAMP causes the dissociation of the inactive holoenzyme into a dimer of regulatory subunits bound to four cAMP and two free monomeric catalytic subunits. Four different regulatory subunits and three catalytic subunits of AMPK have been identified in humans. PKR1 is one of the regulatory subunits. This protein was found to be a tissue-specific extinguisher that down-regulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Functional null mutations in the gene cause Carney complex (CNC), an autosomal dominant multiple neoplasia syndrome. The gene can fuse to the RET protooncogene by gene rearrangement and form the thyroid tumor-specific chimeric oncogene known as PTC2.
Gronholm, M., et al., J. Biol. Chem. 278(42):41167-41172 (2003).Bertherat, J., et al., Cancer Res. 63(17):5308-5319 (2003).Stergiopoulos, S.G., et al., FEBS Lett. 546(1):59-64 (2003).Robinson-White, A., et al., Hum. Mol. Genet. 12(13):1475-1484 (2003).Holm, A.M., et al., J. Immunol. 170(11):5772-5777 (2003).
If you have any additional inquiries please email technical services at email@example.com.